Last checked at 18 Feb 2015 11:08
Eden Research Plc
("Eden" or "Company")
Death of a Director
Eden Research plc (AIM: EDEN), the AIM listed natural micro-encapsulation company, is saddened to announce the death of Clive Roland Newitt, Business Development Director, who passed away on Monday 16 February 2015, aged 58.
Clive had been with the Company since its flotation in May 2012 when he held the position of Managing Director, before he moved into the role of Business Development Director in September 2014.
Sean Smith, Chief Executive Officer of Eden, said: "Clive will be remembered by all of us at Eden. He was a highly valued member of our team and a good friend. He brought a wealth of experience and knowledge to the Company and helped lay the groundwork for the Company's success. My colleagues and I extend our thoughts and deepest sympathy to his family."
Eden Research plc | www.edenresearch.com |
Sean Smith, Chief Executive Officer | Tel: 01993 862 761 |
Alex Abrey, Chief Financial Officer |
|
|
|
W H Ireland Limited | Tel: 0117 945 3471 |
John Wakefield |
|
|
|
Walbrook PR Ltd | Tel: 020 7933 8780 or eden@walbrookpr.com |
Paul McManus Lianne Cawthorne | Mob: 07980 541 893 Mob: 07584 391 303
|
Notes:
Eden is an early stage revenue company with intellectual property and expertise in encapsulation, terpenes and environmentally friendly technologies to provide naturally occurring solutions to the global agrochemicals industry, the animal health industry, and consumer products.
Eden's encapsulation technology harnesses the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can also be used with hydrophobic compounds both natural and synthetic. The technology uses yeast cells to deliver a slow release of natural compounds for agricultural and non-agricultural uses. Terpenes are already widely used in the food flavouring, cosmetic and pharmaceutical industries.
Historically, terpenes have had limited commercial use in the agrochemical sector due to their volatility, phytotoxicity and poor solubility. Eden's platform encapsulation technology provides a unique, environmentally friendly solution to these problems and enables terpenes to be used as effective, low-risk agrochemicals.
With leading consultants in their respective fields, the Company is developing these technologies through innovative research and a series of commercial production, marketing and distribution partnerships.
The Company has a number of patents and has a pipeline of products at differing stages of development targeting specific areas of the global agrochemicals industry. To date, the Company has invested in the region of £12m in developing and protecting its intellectual property. Revenues earned by the Company have been modest whilst the Company has concentrated on securing patent protection for its intellectual property, identifying suitable industrial partners and entering into licence agreements.
Eden was admitted to trading on AIM on 11 May 2012 and trades under the symbol EDEN.
For more information about Eden, please visit www.edenresearch.com